Amylin Pharmaceuticals
To see an up-to date selection of historical analyses and insights on
Amylin Pharmaceuticals,
visit our
new, dynamically updated Company Summary report pages for Amylin Pharmaceuticals.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Amylin Pharmaceuticals are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Amylin Pharmaceuticals,
or on any other Company covered by EvaluatePharma® Contact Us today.
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| Event - Victoza approval could pave the way for Byetta LAR approval
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Victoza's victory could be short lived
|
(Novo Nordisk)
|
(Invalid Date)
|
| Which of 2010's launches will be future blockbusters?
|
(Amgen)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
|
(Alkermes)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
|
(Eli Lilly)
|
(Invalid Date)
|
| Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
|
(Eli Lilly)
|
(Invalid Date)
|
| Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Event – Taspoglutide data adds pressure on Victoza
|
(Ipsen)
|
(Invalid Date)
|
| BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
|
(Eli Lilly)
|
(Invalid Date)
|
| BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) in Head-to-Head DURATION-3 Study
|
(Alkermes)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) in Head-to-Head DURATION-3 Study
|
(Eli Lilly)
|
(Invalid Date)
|
| Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
|
(Alkermes)
|
(Invalid Date)
|
| New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
|
(Eli Lilly)
|
(Invalid Date)
|
| Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control with Weight Loss Over Two Years
|
(Eli Lilly)
|
(Invalid Date)
|
| Interim Study Results Presented at ADA 2009
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control with Weight Loss Over Two Years
|
(Alkermes)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Interim Study Results Presented at ADA 2009
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
|
(Alkermes)
|
(Invalid Date)
|
| Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
|
(Eli Lilly)
|
(Invalid Date)
|
| Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
|
(Eli Lilly)
|
(Invalid Date)
|
| FDA panel review points to DPP-IV success in diabetes market
|
(Novo Nordisk)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
|
(Alkermes)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
|
(Eli Lilly)
|
(Invalid Date)
|
| Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
|
(Amylin Pharmaceuticals)
|
(Invalid Date)
|
| Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
|
(Alkermes)
|
(Invalid Date)
|
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
